Sanofi, GSK Report Successful Vaccine Study Against Omicron
24 Juin 2022 - 8:21AM
Dow Jones News
By Joshua Kirby
Sanofi SA said Friday that its coronavirus booster vaccine,
developed alongside Britain's GSK PLC, has produced successful
results against the Omicron variant of the coronavirus in an
efficacy study.
The French biopharmaceutical company said its vaccine candidate
showed efficacy against the virus in an environment of high Omicron
variation. It showed 72% efficacy against the strain in adult, as
well as a favorable safety and tolerability profile, the company
said.
Along with positive data from two previous trials, the results
will be submitted to regulatory authorities for approval, Sanofi
said.
The results "indicate the potential of Sanofi-GSK's
next-generation Beta-based booster to be a relevant response to
public health needs," the company said.
Write to Joshua Kirby at joshua.kirby@wsj.com;
@joshualeokirby
(END) Dow Jones Newswires
June 24, 2022 02:06 ET (06:06 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Gsk (LSE:GSK)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
